What is the half-life of PE-22-28?

PE-22-28 has a half-life of ~1-2 hours (estimated from preclinical pharmacokinetics), which is why it's typically administered Once daily for optimal therapeutic effect.

How do I reconstitute PE-22-28?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Preclinical

PE-22-28

Also known as: Spadin, PE2228, TREK-1 Channel Blocker Peptide

Overview

Key Facts

Primary Goal: A synthetic heptapeptide derived from the propeptide of the mature form of sortilin

A synthetic heptapeptide derived from the propeptide of the mature form of sortilin. PE-22-28 is a potent and selective blocker of the TREK-1 potassium channel, a validated target for antidepressant and cognitive-enhancing effects. It produces rapid-onset antidepressant-like effects in animal models (within 4 days vs. weeks for SSRIs) and promotes neurogenesis in the hippocampus, making it one of the most promising nootropic peptides in research. Half-Life ~1-2 hours (estimated from preclinical pharmacokinetics) Typical Dose 100–500 mcg Frequency Once daily Cycle Length 4-8 weeks on, 2-4 weeks off

Dosing Information

Half-Life

~1-2 hours (estimated from preclinical pharmacokinetics)

Typical Dose

100–500 mcg

Frequency

Once daily

Cycle Length

4-8 weeks on, 2-4 weeks off

Administration Routes:

subcutaneous

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Note: Protect from light. Do not freeze reconstituted solution.

Research Summary

Preclinical

PE-22-28 (Spadin) was discovered by researchers at the Institut de Pharmacologie Moléculaire et Cellulaire (CNRS, France) and published in Nature Medicine (2010). The team demonstrated that sortilin-derived peptides block TREK-1 channels with high selectivity, producing antidepressant effects in mice within 4 days — compared to 21+ days for fluoxetine. Follow-up studies confirmed hippocampal neurogenesis, increased BDNF expression, and enhanced 5-HT neurotransmission. Behavioral tests (forced swim, tail suspension, novelty-suppressed feeding) consistently showed antidepressant and anxiolytic activity. PE-22-28 represents a novel mechanism entirely distinct from SSRIs, SNRIs, and ketamine-like drugs. Human clinical trials have not yet been conducted.